Jon Burrows
Vorstandsvorsitzender bei OXFORD BIODYNAMICS PLC
Vermögen: 116 435 $ am 30.04.2024
Profil
Jon Burrows is the founder of Oncology Partners LLC.
He is currently the Group Chief Executive Officer & Executive Director at Oxford BioDynamics Plc and the President-Contract Services at RegenETP, Inc. Previously, he served as the President & Chief Executive Officer at OncoPlex Diagnostics, Inc. from 2012 to 2015 and as the Director-Business Development at Ventana Medical Systems, Inc. from 2007 to 2009.
Dr. Burrows completed his undergraduate degree at the University of Leeds and holds graduate and doctorate degrees from The University of Nevada, Reno.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OXFORD BIODYNAMICS PLC
0,35% | 03.04.2024 | 1 088 888 ( 0,35% ) | 116 435 $ | 30.04.2024 |
Aktive Positionen von Jon Burrows
| Unternehmen | Position | Beginn |
|---|---|---|
| REGENETP, INC. | Corporate Officer/Principal | 07.01.2019 |
| OXFORD BIODYNAMICS PLC | Vorstandsvorsitzender | 23.03.2020 |
Ehemalige bekannte Positionen von Jon Burrows
| Unternehmen | Position | Ende |
|---|---|---|
OncoPlex Diagnostics, Inc.
 OncoPlex Diagnostics, Inc. Medical/Nursing ServicesHealth Services OncoPlex Diagnostics, Inc. operates a cancer diagnostics laboratory. It provides information that helps physicians choose targeted therapies and avoid therapies. The company is headquartered in Rockville, MD. | Vorstandsvorsitzender | 01.01.2015 |
Ventana Medical Systems, Inc.
 Ventana Medical Systems, Inc. Electronic Equipment/InstrumentsElectronic Technology Ventana Medical Systems, Inc. develops tissue-based diagnostic solutions. It designs and delivers medical diagnostic systems and slide-based cancer tests. Its products include absolute Eosinophil count (AEC) detection kit intended for laboratory use to identify targets by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded tissue or frozen tissue on a BenchMark and BenchMark XT instrument and DISCOVERY XT research instrument that brings automation, reproducibility, and productivity to IHC and in situ hybridization (ISH) slide preparation and processing. The company was founded by Thomas M. Grogan in 1985 and is headquartered in Phoenix, AZ. | Corporate Officer/Principal | 01.01.2009 |
Oncology Partners LLC
 Oncology Partners LLC Miscellaneous Commercial ServicesCommercial Services Oncology Partners LLC provides strategic and clinical advisory services. The American company was founded by Jon Burrows, Therus C. Kolff. | Gründer | - |
Ausbildung von Jon Burrows
| The University of Nevada, Reno | Doctorate Degree |
| University of Leeds | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| REGENETP, INC. | Health Technology |
| OXFORD BIODYNAMICS PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
OncoPlex Diagnostics, Inc.
OncoPlex Diagnostics, Inc. Medical/Nursing ServicesHealth Services OncoPlex Diagnostics, Inc. operates a cancer diagnostics laboratory. It provides information that helps physicians choose targeted therapies and avoid therapies. The company is headquartered in Rockville, MD. | Health Services |
Oncology Partners LLC
Oncology Partners LLC Miscellaneous Commercial ServicesCommercial Services Oncology Partners LLC provides strategic and clinical advisory services. The American company was founded by Jon Burrows, Therus C. Kolff. | Commercial Services |
Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. Electronic Equipment/InstrumentsElectronic Technology Ventana Medical Systems, Inc. develops tissue-based diagnostic solutions. It designs and delivers medical diagnostic systems and slide-based cancer tests. Its products include absolute Eosinophil count (AEC) detection kit intended for laboratory use to identify targets by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded tissue or frozen tissue on a BenchMark and BenchMark XT instrument and DISCOVERY XT research instrument that brings automation, reproducibility, and productivity to IHC and in situ hybridization (ISH) slide preparation and processing. The company was founded by Thomas M. Grogan in 1985 and is headquartered in Phoenix, AZ. | Electronic Technology |
